PMC7289092 1. Vitamin D Receptor stimulation to reduce Acute Respiratory Distress Syndrome (ARDS) in patients with Coronavirus SARS-CoV-2 infections: Revised Ms SBMB 2020_166.
32535032
PMC7227161 2. Potential Role of ACE2 in Coronavirus Disease 2019 (COVID-19) Prevention and Management.
32435607
PMC7232924 3. Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients.
32423449
PMC7268185 4. SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines.
32493510
PMC7213074 5. Minimum costs to manufacture new treatments for COVID-19.
32405423
PMC7213070 6. Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19.
32405422
PMC7213073 7. A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic?
32405421
PMC7221856 8. SARS-CoV-2 Rates in BCG-Vaccinated and Unvaccinated Young Adults.
32401274
PMC7215635 9. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State.
32392282
PMC7275264 10. Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.
32501511
11. New (re)Purpose for an old drug: purinergic receptor blockade may extinguish the COVID-19 thrombo-inflammatory firestorm.
32530438
12. Intra-Rater and Inter-Rater Reliability of Tongue Coating Diagnosis in Traditional Chinese Medicine Using Smartphones: Quasi-Delphi Study.
32459647
PMC7267264 13. Parenteral Fish-Oil Emulsions in Critically Ill COVID-19 Emulsions.
32384188
PMC7323069 14. Pharmacist's perspective on HCQ treatment of COVID-19.
32533592
15. In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses.
32460458
PMC7211500 16. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.
32401715
PMC7211497 17. Interferon beta-1b for COVID-19.
32401712
PMC7220166 18. Consider pregnancy in COVID-19 therapeutic drug and vaccine trials.
32410758
PMC7255131 19. Chloroquine or hydroxychloroquine for COVID-19: why might they be hazardous?
32450109
PMC7247780 20. Caution against corticosteroid-based COVID-19 treatment.
32464115
PMC7255757 21. The starting line for COVID-19 vaccine development.
32473680
PMC7255193 22. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.
32450106
PMC7239633 23. Vitamin-D and COVID-19: do deficient risk a poorer outcome?
32445630
PMC7255125 24. Hydroxychloroquine prophylaxis for high-risk COVID-19 contacts in India: a prudent approach.
32450054
PMC7255234 25. Death threats after a trial on chloroquine for COVID-19.
32473139
PMC7270824 26. Caution and clarity required in the use of chloroquine for COVID-19.
32518920
PMC7252085 27. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study.
32501454
PMC7282206 28. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.
32518419
PMC7288260 29. Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation.
32528040
PMC7289747 30. Vaccination strategies to combat novel corona virus SARS-CoV-2.
32535078
PMC7289103 31. Virtual screening, ADME/Tox predictions and the drug repurposing concept for future use of old drugs against the COVID-19.
32535080
PMC7263255 32. Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements.
32497632
PMC7245231 33. Crosstalk between endoplasmic reticulum stress and anti-viral activities: A novel therapeutic target for COVID-19.
32454157
PMC7243778 34. Coronaviruses pandemics: Can neutralizing antibodies help?
32450171
PMC7243810 35. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M(pro) enzyme through in silico approach.
32450166
PMC7227533 36. Lungs as target of COVID-19 infection: Protective common molecular mechanisms of vitamin D and melatonin as a new potential synergistic treatment.
32422305
PMC7211740 37. A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials.
32418894
PMC7276916 38. First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19.
32478465
PMC7250763 39. Eficacia de los pulsos de corticoides en pacientes con sindrome de liberacion de citocinas inducido por infeccion por SARS-CoV-2.
32532461
PMC7229965 40. Hidroxicloroquina en el tratamiento del COVID-19: como utilizarla a la espera de evidencia cientifica concluyente.
32425245
PMC7207128 41. Etoposide-based therapy for severe forms of COVID-19.
32416415
PMC7260485 42. Pulmonary delivery of nanostructured lipid carriers for effective repurposing of salinomycin as an antiviral agent.
32516655
PMC7261085 43. N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2.
32504923
PMC7260530 44. Pentoxifylline and complicated COVID-19: A pathophysiologically based treatment proposal.
32485316
PMC7255327 45. Immunopharmacological management of COVID-19: Potential therapeutic role of valproic acid.
32498007
PMC7255216 46. The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast.
32492562
PMC7248637 47. Protective effects of vaccinations and endemic infections on COVID-19: A hypothesis.
32480250
PMC7246001 48. Selenium supplementation in the prevention of coronavirus infections (COVID-19).
32464491
PMC7244432 49. A potential role for cyclophosphamide in the mitigation of acute respiratory distress syndrome among patients with SARS-CoV-2.
32526511
PMC7245270 50. Zinc Iodide in combination with Dimethyl Sulfoxide for treatment of SARS-CoV-2 and other viral infections.
32473509
PMC7244420 51. Survival of COVID-19 patients requires precise immune regulation: The hypothetical immunoprotective role of nicotinic agonists.
32470789
PMC7242962 52. Three novel prevention, diagnostic, and treatment options for COVID-19 urgently necessitating controlled randomized trials.
32534175
PMC7240252 53. Homocysteine as a potential predictor of cardiovascular risk in patients with COVID-19.
32464494
PMC7239001 54. Use of hydroxychloroquine and interferon alpha-2b for the prophylaxis of COVID-19.
32526507
PMC7238987 55. Hypoxia inducible factor-1 protects against COVID-19: A hypothesis.
32464493
PMC7237357 56. Can moderate intensity aerobic exercise be an effective and valuable therapy in preventing and controlling the pandemic of COVID-19?
32464492
PMC7236677 57. Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19.
32460208
PMC7232064 58. Mesenchymal Stem Cells -Bridge Catalyst Between Innte And Adaptive Immunity In Covid 19.
32425307
PMC7229712 59. Protective potential of Expectorants against COVID-19.
32425306
PMC7229719 60. Bioactive compounds with possible inhibitory activity of Angiotensin-Converting Enzyme-II; a gate to manage and prevent COVID-19.
32425303
PMC7217098 61. Exercise as medicine for COVID-19: An ACE in the hole?
32428811
PMC7211747 62. As a potential treatment of COVID-19: Montelukast.
32416408
PMC7252071 63. Lithium chloride combination with rapamycin for the treatment of COVID-19 pneumonia.
32413699
PMC7274964 64. Is hesperidin essential for prophylaxis and treatment of COVID-19 Infection?
32531538
PMC7273142 65. RAGE receptor: May be a potential inflammatory mediator for SARS-COV-2 infection?
32531537
PMC7264927 66. B-cell engineering: A promising approach towards vaccine development for COVID-19.
32516733
PMC7262531 67. Natural RNA dependent RNA polymerase inhibitors: Molecular docking studies of some biologically active alkaloids of Argemone mexicana.
32535456
PMC7263256 68. Diacerein: A potential multi-target therapeutic drug for COVID-19.
32534337
PMC7263226 69. Fighting against frailty and sarcopenia - As well as COVID-19?
32505075
PMC7263242 70. COVID-19 and picotechnology: Potential opportunities.
32505072
PMC7262503 71. Hydrogen peroxide and viral infections: A literature review with research hypothesis definition in relation to the current covid-19 pandemic.
32505069
PMC7272893 72. COVID-19 and implications for thiopurine use.
32400020
PMC7202347 73. SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a Case Report and Review of ABL Kinase Involvement in Viral Infection.
32395220
PMC7250097 74. Commentary: Myths and facts on vitamin D amidst the COVID-19 pandemic.
32470350
PMC7263254 75. Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19.
32497535
PMC7207125 76. Commentary: Could iron chelators prove to be useful as an adjunct to COVID-19 Treatment Regimens?
32418885
PMC7253980 77. A review of South Indian medicinal plant has the ability to combat against deadly viruses along with COVID-19?
32473390
PMC7211703 78. From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development.
32437926
PMC7238991 79. Arbidol/IFN-alpha2b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study.
32445881
PMC7237358 80. Plant Solutions for the COVID-19 Pandemic and Beyond: Historical Reflections and Future Perspectives.
32442649
PMC7291966 81. The Improbability of the Rapid Development of a Vaccine for SARS-CoV-2.
32533920
PMC7227768 82. Can Unconventional Immunomodulatory Agents Help Alleviate COVID-19 Symptoms and Severity?
32404512
PMC7262788 83. Remdesivir for the Treatment of Covid-19 - Preliminary Report.
32445440
PMC7262972 84. Surgery Scheduling in a Crisis.
32445439
PMC7239918 85. Immunogenicity of a DNA vaccine candidate for COVID-19.
32433465
PMC7289229 86. Natural Products as Potential Leads Against Coronaviruses: Could They be Encouraging Structural Models Against SARS-CoV-2?
32529545
PMC7271131 87. COVID-19 vaccines: neutralizing antibodies and the alum advantage.
32499636
PMC7290146 88. Passive antibody therapy in COVID-19.
32533109
PMC7212510 89. BCG-induced trained immunity: can it offer protection against COVID-19?
32393823
PMC7251046 90. Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action.
Naunyn Schmiedebergs Arch Pharmacol 2020; 393 (7): 1153-1156
32462282
PMC7246956 91. Vitamin D can prevent COVID-19 infection-induced multiple organ damage.
Naunyn Schmiedebergs Arch Pharmacol 2020; 393 (7): 1157-1160
32451597
PMC7235439 92. A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19).
Naunyn Schmiedebergs Arch Pharmacol 2020; 393 (7): 1137-1152
32430617
PMC7189353 93. Chloroquine-induced QTc prolongation in COVID-19 patients.
32350818
PMC7267613 94. The Use of Non-invasive Vagus Nerve Stimulation to Treat Respiratory Symptoms Associated With COVID-19: A Theoretical Hypothesis and Early Clinical Experience.
32342609
PMC7239141 95. Beyond Smoking Cessation: Investigating Medicinal Nicotine to Prevent and Treat COVID-19.
32383751
PMC7256035 96. Universal coronavirus vaccines: the time to start is now.
32528732
PMC7248068 97. Certainty of success: three critical parameters in coronavirus vaccine development.
32509338
98. Diet Supplementation, Probiotics, and Nutraceuticals in SARS-CoV-2 Infection: A Scoping Review.
32521760
99. Can Probiotics and Diet Promote Beneficial Immune Modulation and Purine Control in Coronavirus Infection?
32532069
PMC7282726 100. What can we learn about corticosteroid therapy as a treatment for COVID-19?
32519174
PMC7266475 101. COVID-19 infection and oxidative stress: an under-explored approach for prevention and treatment?
32528623
102. The vaccine journey for COVID-19: a comprehensive systematic review of current clinical trials in humans.
32456404
PMC7220573 103. The novel immunomodulatory biologic LMWF5A for pharmacological attenuation of the "cytokine storm" in COVID-19 patients: a hypothesis.
32431755
PMC7247743 104. Repurposing Quaternary Ammonium Compounds as Potential Treatments for COVID-19.
32451736
PMC7228869 105. Demand for potentially hazardous COVID-19 treatments.
32454586
PMC7228862 106. ICER releases pricing models for potential COVID-19 treatments.
32454583
PMC7254006 107. Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system.
32473310
PMC7239792 108. Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19).
32445956
PMC7239007 109. Letter to the Editor in response to the article "Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?"
32445955
PMC7237953 110. A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19).
32442720
PMC7217778 111. Rho kinase inhibitors for SARS-CoV-2 induced acute respiratory distress syndrome: Support from Bartter's and Gitelman's syndrome patients.
32430287
PMC7217799 112. The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?
32430286
{{tp|p=32535032|t=2020. Vitamin D Receptor stimulation to reduce Acute Respiratory Distress Syndrome (ARDS) in patients with Coronavirus SARS-CoV-2 infections: Revised Ms SBMB 2020_166.|pdf=|usr=}}
{{tp|p=32435607|t=2020. Potential Role of ACE2 in Coronavirus Disease 2019 (COVID-19) Prevention and Management.|pdf=|usr=}}
{{tp|p=32423449|t=2020. Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients.|pdf=|usr=}}
{{tp|p=32493510|t=2020. SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines.|pdf=|usr=}}
{{tp|p=32405423|t=2020. Minimum costs to manufacture new treatments for COVID-19.|pdf=|usr=}}
{{tp|p=32405422|t=2020. Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19.|pdf=|usr=}}
{{tp|p=32405421|t=2020. A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic?|pdf=|usr=}}
{{tp|p=32401274|t=2020. SARS-CoV-2 Rates in BCG-Vaccinated and Unvaccinated Young Adults.|pdf=|usr=}}
{{tp|p=32392282|t=2020. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State.|pdf=|usr=}}
{{tp|p=32501511|t=2020. Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.|pdf=|usr=}}
{{tp|p=32530438|t=2020. New (re)Purpose for an old drug: purinergic receptor blockade may extinguish the COVID-19 thrombo-inflammatory firestorm.|pdf=|usr=}}
{{tp|p=32459647|t=2020. Intra-Rater and Inter-Rater Reliability of Tongue Coating Diagnosis in Traditional Chinese Medicine Using Smartphones: Quasi-Delphi Study.|pdf=|usr=}}
{{tp|p=32384188|t=2020. Parenteral Fish-Oil Emulsions in Critically Ill COVID-19 Emulsions.|pdf=|usr=}}
{{tp|p=32533592|t=2020. Pharmacist's perspective on HCQ treatment of COVID-19.|pdf=|usr=}}
{{tp|p=32460458|t=2020. In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses.|pdf=|usr=}}
{{tp|p=32401715|t=2020. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.|pdf=|usr=}}
{{tp|p=32401712|t=2020. Interferon beta-1b for COVID-19.|pdf=|usr=}}
{{tp|p=32410758|t=2020. Consider pregnancy in COVID-19 therapeutic drug and vaccine trials.|pdf=|usr=}}
{{tp|p=32450109|t=2020. Chloroquine or hydroxychloroquine for COVID-19: why might they be hazardous?|pdf=|usr=}}
{{tp|p=32464115|t=2020. Caution against corticosteroid-based COVID-19 treatment.|pdf=|usr=}}
{{tp|p=32473680|t=2020. The starting line for COVID-19 vaccine development.|pdf=|usr=}}
{{tp|p=32450106|t=2020. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.|pdf=|usr=}}
{{tp|p=32445630|t=2020. Vitamin-D and COVID-19: do deficient risk a poorer outcome?|pdf=|usr=}}
{{tp|p=32450054|t=2020. Hydroxychloroquine prophylaxis for high-risk COVID-19 contacts in India: a prudent approach.|pdf=|usr=}}
{{tp|p=32473139|t=2020. Death threats after a trial on chloroquine for COVID-19.|pdf=|usr=}}
{{tp|p=32518920|t=2020. Caution and clarity required in the use of chloroquine for COVID-19.|pdf=|usr=}}
{{tp|p=32501454|t=2020. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study.|pdf=|usr=}}
{{tp|p=32518419|t=2020. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.|pdf=|usr=}}
{{tp|p=32528040|t=2020. Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation.|pdf=|usr=}}
{{tp|p=32535078|t=2020. Vaccination strategies to combat novel corona virus SARS-CoV-2.|pdf=|usr=}}
{{tp|p=32535080|t=2020. Virtual screening, ADME/Tox predictions and the drug repurposing concept for future use of old drugs against the COVID-19.|pdf=|usr=}}
{{tp|p=32497632|t=2020. Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements.|pdf=|usr=}}
{{tp|p=32454157|t=2020. Crosstalk between endoplasmic reticulum stress and anti-viral activities: A novel therapeutic target for COVID-19.|pdf=|usr=}}
{{tp|p=32450171|t=2020. Coronaviruses pandemics: Can neutralizing antibodies help?|pdf=|usr=}}
{{tp|p=32450166|t=2020. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M(pro) enzyme through in silico approach.|pdf=|usr=}}
{{tp|p=32422305|t=2020. Lungs as target of COVID-19 infection: Protective common molecular mechanisms of vitamin D and melatonin as a new potential synergistic treatment.|pdf=|usr=}}
{{tp|p=32418894|t=2020. A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials.|pdf=|usr=}}
{{tp|p=32478465|t=2020. First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19.|pdf=|usr=}}
{{tp|p=32532461|t=2020. Eficacia de los pulsos de corticoides en pacientes con sindrome de liberacion de citocinas inducido por infeccion por SARS-CoV-2.|pdf=|usr=}}
{{tp|p=32425245|t=2020. Hidroxicloroquina en el tratamiento del COVID-19: como utilizarla a la espera de evidencia cientifica concluyente.|pdf=|usr=}}
{{tp|p=32416415|t=2020. Etoposide-based therapy for severe forms of COVID-19.|pdf=|usr=}}
{{tp|p=32516655|t=2020. Pulmonary delivery of nanostructured lipid carriers for effective repurposing of salinomycin as an antiviral agent.|pdf=|usr=}}
{{tp|p=32504923|t=2020. N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2.|pdf=|usr=}}
{{tp|p=32485316|t=2020. Pentoxifylline and complicated COVID-19: A pathophysiologically based treatment proposal.|pdf=|usr=}}
{{tp|p=32498007|t=2020. Immunopharmacological management of COVID-19: Potential therapeutic role of valproic acid.|pdf=|usr=}}
{{tp|p=32492562|t=2020. The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast.|pdf=|usr=}}
{{tp|p=32480250|t=2020. Protective effects of vaccinations and endemic infections on COVID-19: A hypothesis.|pdf=|usr=}}
{{tp|p=32464491|t=2020. Selenium supplementation in the prevention of coronavirus infections (COVID-19).|pdf=|usr=}}
{{tp|p=32526511|t=2020. A potential role for cyclophosphamide in the mitigation of acute respiratory distress syndrome among patients with SARS-CoV-2.|pdf=|usr=}}
{{tp|p=32473509|t=2020. Zinc Iodide in combination with Dimethyl Sulfoxide for treatment of SARS-CoV-2 and other viral infections.|pdf=|usr=}}
{{tp|p=32470789|t=2020. Survival of COVID-19 patients requires precise immune regulation: The hypothetical immunoprotective role of nicotinic agonists.|pdf=|usr=}}
{{tp|p=32534175|t=2020. Three novel prevention, diagnostic, and treatment options for COVID-19 urgently necessitating controlled randomized trials.|pdf=|usr=}}
{{tp|p=32464494|t=2020. Homocysteine as a potential predictor of cardiovascular risk in patients with COVID-19.|pdf=|usr=}}
{{tp|p=32526507|t=2020. Use of hydroxychloroquine and interferon alpha-2b for the prophylaxis of COVID-19.|pdf=|usr=}}
{{tp|p=32464493|t=2020. Hypoxia inducible factor-1 protects against COVID-19: A hypothesis.|pdf=|usr=}}
{{tp|p=32464492|t=2020. Can moderate intensity aerobic exercise be an effective and valuable therapy in preventing and controlling the pandemic of COVID-19?|pdf=|usr=}}
{{tp|p=32460208|t=2020. Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19.|pdf=|usr=}}
{{tp|p=32425307|t=2020. Mesenchymal Stem Cells -Bridge Catalyst Between Innte And Adaptive Immunity In Covid 19.|pdf=|usr=}}
{{tp|p=32425306|t=2020. Protective potential of Expectorants against COVID-19.|pdf=|usr=}}
{{tp|p=32425303|t=2020. Bioactive compounds with possible inhibitory activity of Angiotensin-Converting Enzyme-II; a gate to manage and prevent COVID-19.|pdf=|usr=}}
{{tp|p=32428811|t=2020. Exercise as medicine for COVID-19: An ACE in the hole?|pdf=|usr=}}
{{tp|p=32416408|t=2020. As a potential treatment of COVID-19: Montelukast.|pdf=|usr=}}
{{tp|p=32413699|t=2020. Lithium chloride combination with rapamycin for the treatment of COVID-19 pneumonia.|pdf=|usr=}}
{{tp|p=32531538|t=2020. Is hesperidin essential for prophylaxis and treatment of COVID-19 Infection?|pdf=|usr=}}
{{tp|p=32531537|t=2020. RAGE receptor: May be a potential inflammatory mediator for SARS-COV-2 infection?|pdf=|usr=}}
{{tp|p=32516733|t=2020. B-cell engineering: A promising approach towards vaccine development for COVID-19.|pdf=|usr=}}
{{tp|p=32535456|t=2020. Natural RNA dependent RNA polymerase inhibitors: Molecular docking studies of some biologically active alkaloids of Argemone mexicana.|pdf=|usr=}}
{{tp|p=32534337|t=2020. Diacerein: A potential multi-target therapeutic drug for COVID-19.|pdf=|usr=}}
{{tp|p=32505075|t=2020. Fighting against frailty and sarcopenia - As well as COVID-19?|pdf=|usr=}}
{{tp|p=32505072|t=2020. COVID-19 and picotechnology: Potential opportunities.|pdf=|usr=}}
{{tp|p=32505069|t=2020. Hydrogen peroxide and viral infections: A literature review with research hypothesis definition in relation to the current covid-19 pandemic.|pdf=|usr=}}
{{tp|p=32400020|t=2020. COVID-19 and implications for thiopurine use.|pdf=|usr=}}
{{tp|p=32395220|t=2020. SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a Case Report and Review of ABL Kinase Involvement in Viral Infection.|pdf=|usr=}}
{{tp|p=32470350|t=2020. Commentary: Myths and facts on vitamin D amidst the COVID-19 pandemic.|pdf=|usr=}}
{{tp|p=32497535|t=2020. Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19.|pdf=|usr=}}
{{tp|p=32418885|t=2020. Commentary: Could iron chelators prove to be useful as an adjunct to COVID-19 Treatment Regimens?|pdf=|usr=}}
{{tp|p=32473390|t=2020. A review of South Indian medicinal plant has the ability to combat against deadly viruses along with COVID-19?|pdf=|usr=}}
{{tp|p=32437926|t=2020. From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development.|pdf=|usr=}}
{{tp|p=32445881|t=2020. Arbidol/IFN-alpha2b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study.|pdf=|usr=}}
{{tp|p=32442649|t=2020. Plant Solutions for the COVID-19 Pandemic and Beyond: Historical Reflections and Future Perspectives.|pdf=|usr=}}
{{tp|p=32533920|t=2020. The Improbability of the Rapid Development of a Vaccine for SARS-CoV-2.|pdf=|usr=}}
{{tp|p=32404512|t=2020. Can Unconventional Immunomodulatory Agents Help Alleviate COVID-19 Symptoms and Severity?|pdf=|usr=}}
{{tp|p=32445440|t=2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report.|pdf=|usr=}}
{{tp|p=32445439|t=2020. Surgery Scheduling in a Crisis.|pdf=|usr=}}
{{tp|p=32433465|t=2020. Immunogenicity of a DNA vaccine candidate for COVID-19.|pdf=|usr=}}
{{tp|p=32529545|t=2020. Natural Products as Potential Leads Against Coronaviruses: Could They be Encouraging Structural Models Against SARS-CoV-2?|pdf=|usr=}}
{{tp|p=32499636|t=2020. COVID-19 vaccines: neutralizing antibodies and the alum advantage.|pdf=|usr=}}
{{tp|p=32533109|t=2020. Passive antibody therapy in COVID-19.|pdf=|usr=}}
{{tp|p=32393823|t=2020. BCG-induced trained immunity: can it offer protection against COVID-19?|pdf=|usr=}}
{{tp|p=32462282|t=2020. Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action.|pdf=|usr=}}
{{tp|p=32451597|t=2020. Vitamin D can prevent COVID-19 infection-induced multiple organ damage.|pdf=|usr=}}
{{tp|p=32430617|t=2020. A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19).|pdf=|usr=}}
{{tp|p=32350818|t=2020. Chloroquine-induced QTc prolongation in COVID-19 patients.|pdf=|usr=}}
{{tp|p=32342609|t=2020. The Use of Non-invasive Vagus Nerve Stimulation to Treat Respiratory Symptoms Associated With COVID-19: A Theoretical Hypothesis and Early Clinical Experience.|pdf=|usr=}}
{{tp|p=32383751|t=2020. Beyond Smoking Cessation: Investigating Medicinal Nicotine to Prevent and Treat COVID-19.|pdf=|usr=}}
{{tp|p=32528732|t=2020. Universal coronavirus vaccines: the time to start is now.|pdf=|usr=}}
{{tp|p=32509338|t=2020. Certainty of success: three critical parameters in coronavirus vaccine development.|pdf=|usr=}}
{{tp|p=32521760|t=2020. Diet Supplementation, Probiotics, and Nutraceuticals in SARS-CoV-2 Infection: A Scoping Review.|pdf=|usr=}}
{{tp|p=32532069|t=2020. Can Probiotics and Diet Promote Beneficial Immune Modulation and Purine Control in Coronavirus Infection?|pdf=|usr=}}
{{tp|p=32519174|t=2020. What can we learn about corticosteroid therapy as a treatment for COVID-19?|pdf=|usr=}}
{{tp|p=32528623|t=2020. COVID-19 infection and oxidative stress: an under-explored approach for prevention and treatment?|pdf=|usr=}}
{{tp|p=32456404|t=2020. The vaccine journey for COVID-19: a comprehensive systematic review of current clinical trials in humans.|pdf=|usr=}}
{{tp|p=32431755|t=2020. The novel immunomodulatory biologic LMWF5A for pharmacological attenuation of the "cytokine storm" in COVID-19 patients: a hypothesis.|pdf=|usr=}}
{{tp|p=32451736|t=2020. Repurposing Quaternary Ammonium Compounds as Potential Treatments for COVID-19.|pdf=|usr=}}
{{tp|p=32454586|t=2020. Demand for potentially hazardous COVID-19 treatments.|pdf=|usr=}}
{{tp|p=32454583|t=2020. ICER releases pricing models for potential COVID-19 treatments.|pdf=|usr=}}
{{tp|p=32473310|t=2020. Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system.|pdf=|usr=}}
{{tp|p=32445956|t=2020. Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19).|pdf=|usr=}}
{{tp|p=32445955|t=2020. Letter to the Editor in response to the article "Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?"|pdf=|usr=}}
{{tp|p=32442720|t=2020. A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19).|pdf=|usr=}}
{{tp|p=32430287|t=2020. Rho kinase inhibitors for SARS-CoV-2 induced acute respiratory distress syndrome: Support from Bartter's and Gitelman's syndrome patients.|pdf=|usr=}}
{{tp|p=32430286|t=2020. The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?|pdf=|usr=}}